Active antibiotic discontinuation in suspected but not confirmed early-onset neonatal sepsis-A quality improvement initiative.


Journal

Acta paediatrica (Oslo, Norway : 1992)
ISSN: 1651-2227
Titre abrégé: Acta Paediatr
Pays: Norway
ID NLM: 9205968

Informations de publication

Date de publication:
06 2020
Historique:
received: 31 10 2019
revised: 25 12 2019
accepted: 27 01 2020
pubmed: 31 1 2020
medline: 15 5 2021
entrez: 31 1 2020
Statut: ppublish

Résumé

To study whether a simple targeted intervention could reduce unwarranted antibiotic treatment in near-term and term neonates with suspected, but not confirmed early-onset sepsis. A quality improvement initiative in three Norwegian neonatal intensive care units. The intervention included an inter-hospital clinical practice guideline for discontinuing antibiotics after 36-48 hours if sepsis was no longer suspected and blood cultures were negative in neonates ≥ 34+0 weeks of gestation. Two units used procalcitonin in decision-making. We compared data 12-14 months before and after guideline implementation. The results are presented as median with interquartile ranges. A total of 284 infants (2.5% of all births ≥ 34+0 weeks of gestation) received antibiotics before and 195 (1.8%) after guideline implementation (P = .0018). The two units that used procalcitonin discontinued antibiotics earlier after guideline implementation than the unit without procalcitonin. Neonates not diagnosed with sepsis were treated 49 (31-84) hours before and 48 (36-72) hours after guideline implementation (P = .68). In all infants, including those diagnosed with sepsis, antibiotic treatment duration was reduced from 108 (60-144) to 96 (48-120) hours (P = .013). Antibiotic treatment duration for suspected, but not confirmed early-onset sepsis did not change. However, treatment duration for all infants and the proportion of infants commenced on antibiotics were reduced.

Identifiants

pubmed: 31999863
doi: 10.1111/apa.15202
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1125-1130

Informations de copyright

© 2020 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.

Références

Cantey JB, Baird SD. Ending the Culture of Culture-Negative Sepsis in the Neonatal ICU. Pediatrics. 2017;140(4):e20170044.
Cantey JB, Wozniak PS, Pruszynski JE, Sanchez PJ. Reducing unnecessary antibiotic use in the neonatal intensive care unit (SCOUT): a prospective interrupted time-series study. Lancet Infect Dis. 2016;16:1178-1184.
Fjalstad JW, Esaiassen E, Juvet LK, van den Anker JN, Klingenberg C. Antibiotic therapy in neonates and impact on gut microbiota and antibiotic resistance development: a systematic review. J Antimicrob Chemother. 2018;73:569-580.
Esaiassen E, Fjalstad JW, Juvet LK, van den Anker JN, Klingenberg C. Antibiotic exposure in neonates and early adverse outcomes: a systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:1858-1870.
Ho T, Dukhovny D, Zupancic JA, Goldmann DA, Horbar JD, Pursley DM. Choosing wisely in newborn medicine: Five opportunities to increase value. Pediatrics. 2015;136:e482-e489.
Puopolo KM, Benitz WE, Zaoutis TE. Management of neonates born at >/=35 0/7 Weeks' gestation with suspected or proven early-onset bacterial sepsis. Pediatrics. 2018;142:e20182894.
Caffrey OE, Prentice P. NICE clinical guideline: antibiotics for the prevention and treatment of early-onset neonatal infection. Arch Dis Child Educ Pract Ed. 2014;99:98-100.
Fjalstad JW, Stensvold HJ, Bergseng H, et al. Early-onset sepsis and antibiotic exposure in term infants: A nationwide population-based study in Norway. Pediatr Infect Dis J. 2016;35:1-6.
Stocker M, van HW, El HS, Dutta S, Fontana MS, Schuerman FABA, , et al. Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns). Lancet. 2017;390:871-881.
Tolia VN, Desai S, Qin H, et al. Implementation of an automatic stop order and initial antibiotic exposure in very low birth weight infants. Am J Perinatol. 2017;34:105-110.
Astorga MC, Piscitello KJ, Menda N, et al. Antibiotic stewardship in the neonatal intensive care unit: Effects of an automatic 48-hour antibiotic stop order on antibiotic use. J Pediatric Infect Dis Soc. 2019;8:310-316.
Stocker M, Fontana M, El HS, Wegscheider K, Berger TM. Use of procalcitonin-guided decision-making to shorten antibiotic therapy in suspected neonatal early-onset sepsis: prospective randomized intervention trial. Neonatology. 2010;97:165-174.
Polin RA. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics. 2012;129:1006-1015.
Mjelle AB, Guthe HJT, Reigstad H, Bjorke-Monsen AL, Markestad T. Serum concentrations of C-reactive protein in healthy term-born Norwegian infants 48-72 hours after birth. Acta Paediatr. 2019;108:849-854.
Schulman J, Dimand RJ, Lee HC, Duenas GV, Bennett MV, Gould JB. Neonatal intensive care unit antibiotic use. Pediatrics. 2015;135:826-833.
Rasmussen RA, Hofmann-Lehman R, Montefiori DC, et al. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J Med Primatol. 2002;31:40-60.
Mitre E, Susi A, Kropp LE, Schwartz DJ, Gorman GH, Nylund CM. Association between use of acid-suppressive medications and antibiotics during infancy and allergic diseases in early childhood. JAMA Pediatr. 2018;172(6):e180315.
Ho T, Buus-Frank ME, Edwards EM, et al. Adherence of newborn-specific antibiotic stewardship programs to CDC recommendations. Pediatrics. 2018;142(6):e20174322.
Duvoisin G, Fischer C, Maucort-Boulch D, Giannoni E. Reduction in the use of diagnostic tests in infants with risk factors for early-onset neonatal sepsis does not delay antibiotic treatment. Swiss Med Wkly. 2014;144:w13981.
Kuzniewicz MW, Puopolo KM, Fischer A, et al. A quantitative, risk-based approach to the management of neonatal early-onset sepsis. JAMA Pediatr. 2017;171:365-371.

Auteurs

Thomas Dretvik (T)

Department of Paediatric and Adolescent Medicine, Akershus University Hospital, Lørenskog, Norway.

Anne Lee Solevåg (AL)

Department of Paediatric and Adolescent Medicine, Akershus University Hospital, Lørenskog, Norway.

Andreas Finvåg (A)

Paediatric Research Group, Faculty of Health Sciences, UiT-The Arctic University of Norway, Tromsø, Norway.

Eline Hasselgård Størdal (EH)

Faculty of Medicine, University of Oslo, Oslo, Norway.

Ketil Størdal (K)

Paediatric Department, Ostfold Hospital Trust, Fredrikstad, Norway.
Department of non-communicable diseases, Norwegian Institute of Public Health, Oslo, Norway.

Claus Klingenberg (C)

Paediatric Research Group, Faculty of Health Sciences, UiT-The Arctic University of Norway, Tromsø, Norway.
Department of Paediatrics and Adolescence Medicine, University Hospital of North Norway, Tromsø, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH